Ceftriaxone for the Treatment of Methicillin-susceptible Bacteremia: A Case Series.

Methicillin-susceptible (MSSA) causes 45% of bloodstream infections (BSI) and is the most important cause of BSI-associated death. The standard of care therapy is an anti-staphylococcal penicillin or cefazolin, but dosing frequencies for these agents are often infeasible; multiple daily doses tie up infusion lines and are impractical for outpatient antibiotic infusion. Ceftriaxone represents a promising alternative, with once daily dosing and a short infusion time.